Abstract
S18616 {(S)-spiro[(1-oxa-2-amino-3-azacyclopent-2-ene)-4,2′-(8′-chloro-1′,2′,3′,4′-tetrahydronaphthalene)]} displayed high affinity at native rat α2-adrenoceptors (AR)s (pKi, 9.8), native human (h)α2A-ARs (9.6), and cloned hα2A- (9.5), hα2B- (9.2), and hα2C- (9.0) ARs. It showed 40-fold lower affinity for hα1A-ARs (8.4) and ≥100-fold lower affinity for rat α1-ARs (7.1), hα1B-ARs (7.7), hα1D-ARs (7.6), imidazoline1 (7.4), and imidazoline2 (7.4) sites and >100-fold lower affinity for all other (>50) sites. At hα2A-ARs, in guanosine-5′-O-(3-[35S]thio)triphosphate binding studies, S18616 was a potent (partial) agonist: log effective concentration (pEC50), 9.3/maximal effect, 51%. This observation was corroborated employing a hα2A-Gi1α fusion protein/GTPase assay (9.0/40%) in which the actions of S18616 were blocked by pertussis toxin. Employing guanosine-5′-O-(3-[35S]thio)triphosphate binding assays, S18616 was also a partial agonist at hα2C-ARs (8.2/63%) but a full agonist (8.4/124%) at hα2B-ARs. At hα2A-, hα2B-, and hα2C-ARs, the selective α2-AR antagonist, atipamezole, abolished the actions of S18616: pKb values of 9.1, 9.1, and 9.4, respectively. As determined by depletion of membrane-bound [3H]phosphatidyl inositols, S18616 behaved as a (less potent) agonist (7.8/79%) at hα1A-ARs, an action abolished by prazosin (pKb, 8.9). Reflecting α2-AR agonist properties, S18616 potently (≥1 μg/kg, s.c.) and dose dependently elicited hypothermia and antinociception (nine diverse models) in rodents. These actions were dose dependently inhibited by chemically diverse α2- versus α1-AR antagonists, atipamezole, idazoxan, RX821,002, and BRL44418 (a preferential α2A-AR ligand). In contrast, the actions of S18616 were unaffected by the α1-AR antagonists, ARC239 and prazosin (which preferentially block α2B/2C- versus α2A-ARs). Although the affinity of dexmedetomidine at α2-ARs was lower than S18616; it displayed a similar receptor and functional profile. Clonidine displayed lower efficacy than S18616, was substantially less potent, and had marked affinity for imidazoline1 sites and α1-ARs. In conclusion, S18616 is a novel, selective, and highly potent agonist at α2-ARs.
Footnotes
-
Send reprint requests to: Dr. Mark J. Millan, Institut de Recherches Servier, Centre de Recherches de Croissy, Psychopharmacology Department, 125 Chemin de Ronde, Croissy/Seine 78290, France.
-
↵1 Although porcine and human α2A-ARs are identical, the “α2D-AR” of rats and mice are orthologous to the human α2A-AR from which they may be distinguished by their pattern of interaction with various classes of ligand (Bylund et al., 1994; O'Rourke et al., 1994; Renouard et al., 1994; Hieble et al., 1995). Herein, to avoid confusion, we refer, in a species-specific manner, to hα2A-, pα2A-, mα2A-, and rα2A-ARs.
- Abbreviations:
- NE
- norepinephrine
- AR
- adrenoceptor
- CHO
- Chinese hamster ovary
- CT
- core temperature
- [35S]GTPγS
- guanosine-5′-O-(3-[35S]thio)triphosphate
- MAO
- monoamine oxidase
- PI
- phosphatidyl inositol
- TF
- tail-flick
- STF
- spontaneous tail-flick
- 5-HT
- serotonin
- S18616
- (S)-spiro[(1-oxa-2-amino-3-azacyclopent-2-ene)-4,2′-(8′-chloro-1′,2′,3′,4′-tetrahydronaphthalene)]
- 8-OH-DPAT
- (±)-8-dihydroxy-2-(di-n-propylamino)tetralin
- 4-DAMP
- 4-diphenylacetoxy-N-methylpiperidine methiodide
- Received June 1, 2000.
- Accepted August 16, 2000.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|